Summary

Multiparametric Molecular Imaging
Molecular imaging (MI) is paving the way for precision and personalized medicine. Molecular imaging techniques using radiolabeled pharmaceuticals and positron-emission-tomography (PET) are increasingly used for the assessment of pathobiochemical and pathophysiological changes in oncology and neurology.
We aim to test and to implement new molecular imaging probes for different oncological and neurological diseases, in order to obtain a better characterization of the underlying molecular changes in vivo.
New generation hybrid PET-MR scanner enable the simultaneous acquisition of molecular (PET) as well as morphological and functional (chemical shifts, flow, diffusion, blood oxygenation and perfusion) changes (MR) in vivo, that might give new insights in the oncological processes.
We aim to use those multi-parametric imaging techniques in order to provide an insight in physiological (adaptive) as well as pathophysiological changes, which might lead to an individualized treatment stratification for our patients in the future.